Alibaba Group Holding Ltd (BABA) Q1 2022 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Operator
Good day, ladies and gentlemen. Thank you for standing by. Welcome to Alibaba Group s March quarter 2021 and full fiscal-year 2021 results conference call. [Operator instructions] After management s prepared remarks, there will be a question-and-answer session.
Now, I d like to turn the call over to Rob Lin, head of investor relations of Alibaba Group. Please go ahead.
Rob Lin
Head of Investor Relations
Good day and good evening, everyone, and welcome to Alibaba Group s March quarter 2021 and full fiscal-year 2021 results conference call. With us today are Daniel Zhang, our chairman and CEO; Joe Tsai, executive vice chairman; Maggie Wu, chief financial officer. This call is also being webcast from the IR section of our corporate website. A replay of the call will be available on our website later today.
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
04/20/2021 | 09:00am EDT
Send by mail :
Message :
20 April 2021
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. (“Code Bio” or the ”Company”), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated in the start-up process and co-led the financing alongside UPMC Enterprises, with participation from CureDuchenne Ventures, The JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures, Inc.
4Bio Capital: 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
20 April 2021
LONDON & BOSTON - 4BIO Capital ( 4BIO or the Group ), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. ( Code Bio or the Company ), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated in the start-up process and co-led the financing alongside UPMC Enterprises, with participation from CureDuchenne Ventures, The JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures, Inc.